These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Recent progress in mycobacteriology]. Okada M; Kobayashi K Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602 [TBL] [Abstract][Full Text] [Related]
3. Preclinical Progress of Subunit and Live Attenuated Watt J; Liu J Pharmaceutics; 2020 Sep; 12(9):. PubMed ID: 32899930 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis. Tchilian EZ; Desel C; Forbes EK; Bandermann S; Sander CR; Hill AV; McShane H; Kaufmann SH Infect Immun; 2009 Feb; 77(2):622-31. PubMed ID: 19064635 [TBL] [Abstract][Full Text] [Related]
5. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Horwitz MA; Harth G; Dillon BJ; Maslesa-Galic' S Proc Natl Acad Sci U S A; 2000 Dec; 97(25):13853-8. PubMed ID: 11095745 [TBL] [Abstract][Full Text] [Related]
6. Jia Q; Masleša-Galić S; Nava S; Horwitz MA mBio; 2022 Jun; 13(3):e0068722. PubMed ID: 35642945 [TBL] [Abstract][Full Text] [Related]
7. Tuberculosis vaccines: beyond bacille Calmette-Guerin. McShane H Philos Trans R Soc Lond B Biol Sci; 2011 Oct; 366(1579):2782-9. PubMed ID: 21893541 [TBL] [Abstract][Full Text] [Related]
8. Next-Generation Vaccines Based on Bacille Calmette-Guérin. Nieuwenhuizen NE; Kaufmann SHE Front Immunol; 2018; 9():121. PubMed ID: 29459859 [TBL] [Abstract][Full Text] [Related]
9. Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis? Moliva JI; Turner J; Torrelles JB Vaccine; 2015 Sep; 33(39):5035-41. PubMed ID: 26319069 [TBL] [Abstract][Full Text] [Related]
10. Tuberculosis vaccine development at a divide. Kaufmann SH Curr Opin Pulm Med; 2014 May; 20(3):294-300. PubMed ID: 24626237 [TBL] [Abstract][Full Text] [Related]
11. Non-Tuberculous Mycobacteria Interference with BCG-Current Controversies and Future Directions. Verma D; Chan ED; Ordway DJ Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33207695 [TBL] [Abstract][Full Text] [Related]
12. Vaccines for Leprosy and Tuberculosis: Opportunities for Shared Research, Development, and Application. Coppola M; van den Eeden SJF; Robbins N; Wilson L; Franken KLMC; Adams LB; Gillis TP; Ottenhoff THM; Geluk A Front Immunol; 2018; 9():308. PubMed ID: 29535713 [TBL] [Abstract][Full Text] [Related]
13. [Novel vaccines against M. tuberculosis]. Okada M Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920 [TBL] [Abstract][Full Text] [Related]
14. Natural and trained innate immunity against Mycobacterium tuberculosis. Ferluga J; Yasmin H; Al-Ahdal MN; Bhakta S; Kishore U Immunobiology; 2020 May; 225(3):151951. PubMed ID: 32423788 [TBL] [Abstract][Full Text] [Related]
15. Immune Responses to Bacillus Calmette-Guérin Vaccination: Why Do They Fail to Protect against Moliva JI; Turner J; Torrelles JB Front Immunol; 2017; 8():407. PubMed ID: 28424703 [No Abstract] [Full Text] [Related]
19. [BCG vaccines for the prevention of tuberculosis in the world]. Hashimoto T Kekkaku; 1997 Nov; 72(11):629-37. PubMed ID: 9423301 [TBL] [Abstract][Full Text] [Related]
20. An Overview of the Development of New Vaccines for Tuberculosis. Whitlow E; Mustafa AS; Hanif SNM Vaccines (Basel); 2020 Oct; 8(4):. PubMed ID: 33027958 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]